These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38735022)

  • 1. Correction: The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.
    Cong L; Deng Y; Cai S; Wang G; Zhao X; He J; Zhao S; Wang L
    Insights Imaging; 2024 May; 15(1):117. PubMed ID: 38735022
    [No Abstract]   [Full Text] [Related]  

  • 2. The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.
    Cong L; Deng Y; Cai S; Wang G; Zhao X; He J; Zhao S; Wang L
    Insights Imaging; 2024 Feb; 15(1):64. PubMed ID: 38411746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of contrast-enhanced portal vein imaging at the hepatobiliary phase obtained with gadobenate dimeglumine for predicting decompensation and transplant-free survival in chronic liver disease.
    Cai S; Lin N; Yang Y; Ma W; Wang Y; Lin X; Wang X; Zhao X
    Eur Radiol; 2023 May; 33(5):3425-3434. PubMed ID: 36897349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
    Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
    AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA.
    Vernuccio F; Bruno A; Costanzo V; Bartolotta TV; Vieni S; Midiri M; Salvaggio G; Brancatelli G
    Curr Probl Diagn Radiol; 2020; 49(6):398-403. PubMed ID: 31253462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.
    Zhang L; Yu X; Huo L; Lu L; Pan X; Jia N; Fan X; Morana G; Grazioli L; Schneider G
    Eur Radiol; 2019 Oct; 29(10):5205-5216. PubMed ID: 30915560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
    Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
    Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
    Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
    AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
    Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
    Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of gadobenate dimeglumine-induced anaphylactic shock: a case report.
    Huang J; Liu Z; Jiang C; Xu L; Zheng W
    Ann Palliat Med; 2021 Jun; 10(6):7126-7131. PubMed ID: 34154335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.
    Meng D; Liang C; Zheng Y; Wang X; Liu K; Lin Z; Zhu Q; Zhao X
    Eur Radiol; 2022 Dec; 32(12):8608-8616. PubMed ID: 35639146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
    Liu C; Sun Y; Yang Y; Feng Y; Xie X; Qi L; Liu K; Wang X; Zhu Q; Zhao X
    Eur Radiol; 2021 Aug; 31(8):5840-5850. PubMed ID: 33533990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
    Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
    Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-Radiologic Morphology-Radiomics Model on Gadobenate Dimeglumine-Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation.
    Zheng W; Chen X; Xiong M; Zhang Y; Song Y; Cao D
    J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38375988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.
    Frydrychowicz A; Nagle SK; D'Souza SL; Vigen KK; Reeder SB
    J Magn Reson Imaging; 2011 Sep; 34(3):585-94. PubMed ID: 21751288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.